Dr. Maria T. Millan, President and CEO of CIRM, presenting the President's Report This past Thursday the governing Board of the California Institute for Regenerative Medicine (CIRM) were presented with an update on CIRM’s clinical portfolio, which to date includes 60 clinical trials in various areas including kidney failure, cancer, and other rare diseases. The … Continue reading CIRM Board Meeting Highlights Important Updates to Clinical Trials
Cancer
Rave reviews for new Killer-T Cell study
Anytime you read a news headline that claims a new discovery "may treat all cancer" it's time to put your skeptic's hat on. After all, there have been so many over-hyped "discoveries" over the years that later flopped, that it would be natural to question the headline writer. And yet, this time, maybe, this one … Continue reading Rave reviews for new Killer-T Cell study
It’s official: the state of regenerative medicine is strong
A panel discussion to a packed house at the annual ARM State of the Industry briefing Calling it a “year of dramatic impact for patients” Janet Lambert, the CEO of the Alliance for Regenerative Medicine (ARM), gave the annual “State of the Industry” briefing today in San Francisco. The briefing is a traditional kick-off event … Continue reading It’s official: the state of regenerative medicine is strong
Journalism Pioneer and Founder of Latino Cancer Institute Joins Stem Cell Agency Board
Ysabel Duron Ysabel Duron, a pioneering award-winning Latina journalist, and a leading figure in cancer education in the Latino community in the US, has been appointed to the governing Board of the California Institute for Regenerative Medicine. State Controller Betty Yee made the appointment saying: “Ms. Duron’s personal perspective as a (cancer) survivor and … Continue reading Journalism Pioneer and Founder of Latino Cancer Institute Joins Stem Cell Agency Board
An off-the-shelf cancer killer
iPS Cell: Photo from the lab of Kathrin Plath at UCLA One of the hottest areas in cancer research right now is the use of CAR-T treatments. These use the patient’s own re-engineered immune system cells to target and kill the tumor. But the thing that makes it so appealing – using the patient’s own … Continue reading An off-the-shelf cancer killer
Four CIRM Funded Trials Release Results at 2019 ASH Meeting
With more than 17,000 members from nearly 100 countries, the American Society of Hematology (ASH) is an organization composed of clinicians and scientists around the world working to conquer various blood diseases. Currently, they are having their 61st Annual ASH Meeting to highlight some of the exciting work going on in the field. Four of … Continue reading Four CIRM Funded Trials Release Results at 2019 ASH Meeting
Researchers create a better way to grow blood stem cells
UCLA's Dr. Hanna Mikkola and Vincenzo Calvanese, lead scientists on the study. Photo courtesy UCLA Blood stem cells are a vital part of us. They create all the other kinds of blood cells in our body and are used in bone marrow transplants to help people battling leukemia or other blood cancers. The problem is … Continue reading Researchers create a better way to grow blood stem cells
CIRM Board Awards $15.8 Million to Four Translational Research Projects
Last week, the CIRM Board approved $32.92 million in awards directed towards four new clinical trials in vision related diseases and Parkinson's Disease. In addition to these awards, the Board also approved investing $15.80 million in four awards in the Translational Research program. The goal of this program is to help promising projects complete the … Continue reading CIRM Board Awards $15.8 Million to Four Translational Research Projects
How early CIRM support helped an anti-cancer therapy overcome obstacles and help patients
Dr. Catriona Jamieson, UC San Diego When you read about a new drug or therapy being approved to help patients it always seems so simple. Researchers come up with a brilliant idea, test it to make sure it is safe and works, and then get approval from the US Food and Drug Administration (FDA) to … Continue reading How early CIRM support helped an anti-cancer therapy overcome obstacles and help patients
USC study shows how tumor cells in the bloodstream can target distant organs
Various types of cancer can become particularly aggressive and difficult to treat once they spread from their initial point of origin to other parts of the body. This unfortunate phenomenon, known as metastasis, can make treatment very challenging, decreasing the chance of survival for the patient. In order to better understand this process, a CIRM … Continue reading USC study shows how tumor cells in the bloodstream can target distant organs